These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27079872)

  • 1. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
    Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
    Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples.
    Jagarlamudi KK; L S; M Z; J O; P V; S E
    PLoS One; 2022; 17(10):e0275444. PubMed ID: 36201558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
    Jagarlamudi KK; Hansson LO; Eriksson S
    BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AroCell TK 210 ELISA for determination of TK1 protein: age-related reference ranges and comparison with other TK1 assays.
    Kumar JK; Holmgren S; Levedahl KH; Höglund M; Venge P; Eriksson S
    Biotechniques; 2020 Jun; 68(6):334-341. PubMed ID: 32336110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management.
    Jagarlamudi KK; Moreau L; Westberg S; Rönnberg H; Eriksson S
    PLoS One; 2015; 10(9):e0137871. PubMed ID: 26366881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.
    Jagarlamudi KK; Zupan M; Kumer K; Fabjan T; Hlebič G; Eriksson S; Osredkar J; Smrkolj T
    Prostate; 2019 Jun; 79(8):856-863. PubMed ID: 30889628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer.
    Carlsson L; Larsson A; Lindman H
    Ups J Med Sci; 2009; 114(2):116-20. PubMed ID: 19396699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can thymidine kinase levels in breast tumors predict disease recurrence?
    O'Neill KL; Hoper M; Odling-Smee GW
    J Natl Cancer Inst; 1992 Dec; 84(23):1825-8. PubMed ID: 1433372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
    Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
    Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer.
    Alegre MM; Weyant MJ; Bennett DT; Yu JA; Ramsden MK; Elnaggar A; Robison RA; O'Neill KL
    Anticancer Res; 2014 May; 34(5):2145-51. PubMed ID: 24778016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.
    Bjöhle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Söderberg M; Sundquist M; Walz TM; Fernö M; Bergh J; Hatschek T
    Breast Cancer Res Treat; 2013 Jun; 139(3):751-8. PubMed ID: 23736998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thymidine kinase 1 activity in breast cancer.
    Nisman B; Allweis T; Kaduri L; Maly B; Gronowitz S; Hamburger T; Peretz T
    Cancer Biomark; 2010; 7(2):65-72. PubMed ID: 21178264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.
    Jagarlamudi KK; Shaw M
    Biomark Med; 2018 Sep; 12(9):1035-1048. PubMed ID: 30039979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
    Wang Z; Zhang W; Huo B; Dong L; Zhang J
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development.
    Jagarlamudi KK; Wang L; Eriksson S
    Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):679-686. PubMed ID: 30520339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.
    Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S
    BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.
    McKenna PG; O'Neill KL; Abram WP; Hannigan BM
    Br J Cancer; 1988 Jun; 57(6):619-22. PubMed ID: 3408646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?
    Attallah AM; El-Far M; Omran MM; Abdallah SO; El-Desouky MA; El-Dosoky I; Abdelrazek MA; Attallah AA; Elweresh MA; Abdel Hameed GE; Shawki HA; Salama KS; El-Waseef AM
    Tumour Biol; 2014 Nov; 35(11):10737-45. PubMed ID: 25073515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.